TitleAssistant Professor
InstitutionMD Anderson
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Pham LV, Huang S, Zhang H, Zhang J, Bell T, Zhou S, Pogue E, Ding Z, Lam L, Westin J, Davis RE, Young KH, Medeiros LJ, Ford RJ, Nomie K, Zhang L, Wang M. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas. Clin Cancer Res. 2018 08 15; 24(16):3967-3980. PMID: 29666304.
      Citations: 30     Fields:    Translation:HumansAnimalsCells
    2. Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Zhang L, Baher L, Cheng M, Lee D, Beaupre DM, Rule S. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015 Aug 06; 126(6):739-45. PMID: 26059948; PMCID: PMC4528064.
      Citations: 124     Fields:    Translation:HumansCTClinical Trials
    3. Gao W, Wang M, Wang L, Lu H, Wu S, Dai B, Ou Z, Zhang L, Heymach JV, Gold KA, Minna J, Roth JA, Hofstetter WL, Swisher SG, Fang B. Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells. J Natl Cancer Inst. 2014 Sep; 106(9). PMID: 25214559; PMCID: PMC4200057.
      Citations: 51     Fields:    Translation:HumansAnimalsCells
    4. Garcia MK, Cohen L, Guo Y, Zhou Y, You B, Chiang J, Orlowski RZ, Weber D, Shah J, Alexanian R, Thomas S, Romaguera J, Zhang L, Badillo M, Chen Y, Wei Q, Lee R, Delasalle K, Green V, Wang M. Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. J Hematol Oncol. 2014 May 09; 7:41. PMID: 24886772; PMCID: PMC4038108.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    5. Pham LV, Vang MT, Tamayo AT, Lu G, Challagundla P, Jorgensen JL, Rollo AA, Ou Z, Zhang L, Wang M, Ford RJ. Involvement of tumor-associated macrophage activation in vitro during development of a novel mantle cell lymphoma cell line, PF-1, derived from a typical patient with relapsed disease. Leuk Lymphoma. 2015 Jan; 56(1):186-93. PMID: 24611650; PMCID: PMC5779854.
      Citations: 6     Fields:    Translation:HumansCells
    6. Cai Q, Westin J, Fu K, Desai M, Zhang L, Huang H, Jiang W, Liang R, Qian Z, Champlin RE, Wang M. Accelerated therapeutic progress in diffuse large B cell lymphoma. Ann Hematol. 2014 Apr; 93(4):541-56. PMID: 24375125.
      Citations: 10     Fields:    Translation:HumansAnimals
    7. Zhang L, Pham LV, Newberry KJ, Ou Z, Liang R, Qian J, Sun L, Blonska M, You Y, Yang J, Lin X, Rollo A, Tamayo AT, Lee J, Ford RJ, Zhao X, Kwak LW, Yi Q, Wang M. In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome. Mol Cancer Ther. 2013 Nov; 12(11):2494-504. PMID: 23990113.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    8. Axelrod M, Ou Z, Brett LK, Zhang L, Lopez ER, Tamayo AT, Gordon V, Ford RJ, Williams ME, Pham LV, Weber MJ, Wang ML. Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma. Leukemia. 2014 Feb; 28(2):407-10. PMID: 23979520; PMCID: PMC3918872.
      Citations: 16     Fields:    Translation:HumansCells
    9. Desai M, Newberry KJ, Romaguera J, Zhang L, Ou Z, Wang M. Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy. J Hematol Oncol. 2013 Aug 02; 6:55. PMID: 23915913; PMCID: PMC3735404.
      Citations: 6     Fields:    Translation:HumansAnimals
    10. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013 Aug 08; 369(6):507-16. PMID: 23782157; PMCID: PMC4513941.
      Citations: 553     Fields:    Translation:HumansCTClinical Trials
    11. Zhang L, Newberry KJ, Wang M. Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment. Expert Rev Clin Immunol. 2013 Jun; 9(6):495-7. PMID: 23730878.
      Citations:    Fields:    Translation:HumansAnimals
    12. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad L. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013 Sep; 27(9):1902-9. PMID: 23545991.
      Citations: 65     Fields:    Translation:HumansCTClinical Trials
    13. Zhang K, Wang M, Tamayo AT, Shacham S, Kauffman M, Lee J, Zhang L, Ou Z, Li C, Sun L, Ford RJ, Pham LV. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp Hematol. 2013 Jan; 41(1):67-78.e4. PMID: 22986101.
      Citations: 63     Fields:    Translation:HumansAnimalsCells
    14. Zhang L, Yang J, Qian J, Li H, Romaguera JE, Kwak LW, Wang M, Yi Q. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood. 2012 Nov 01; 120(18):3783-92. PMID: 22968454; PMCID: PMC3488890.
      Citations: 51     Fields:    Translation:HumansAnimals
    15. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak L, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera J. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 2012 Jul; 13(7):716-23. PMID: 22677155.
      Citations: 89     Fields:    Translation:HumansCTClinical Trials
    16. Zheng Y, Yang J, Qian J, Zhang L, Lu Y, Li H, Lin H, Lan Y, Liu Z, He J, Hong S, Thomas S, Shah J, Baladandayuthapani V, Kwak LW, Yi Q. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. J Mol Med (Berl). 2012 Jun; 90(6):695-706. PMID: 22207485; PMCID: PMC4212830.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    17. Sun L, Zhang L, Qian J, Yang J, Yi Q, Dong W, Wang M. Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo. Leuk Res. 2012 Mar; 36(3):363-8. PMID: 22000823.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    18. Scott LJ, Lyseng-Williamson KA. Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs. 2011 Mar 26; 71(5):625-49. PMID: 21443285.
      Citations: 10     Fields:    Translation:HumansAnimals
    19. Qian Z, Zhang L, Cai Z, Sun L, Wang H, Yi Q, Wang M. Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leuk Res. 2011 Mar; 35(3):380-6. PMID: 21047686.
      Citations: 29     Fields:    Translation:HumansAnimalsCells
    20. Zhang L, Qian Z, Cai Z, Sun L, Wang H, Bartlett JB, Yi Q, Wang M. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol. 2009 Sep; 84(9):553-9. PMID: 19565649.
      Citations: 57     Fields:    Translation:HumansAnimalsCells
    21. Qian J, Hong S, Wang S, Zhang L, Sun L, Wang M, Yang J, Kwak LW, Hou J, Yi Q. Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma. Blood. 2009 Oct 29; 114(18):3880-9. PMID: 19654406; PMCID: PMC2773487.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    22. Wang M, Sun L, Qian J, Han X, Zhang L, Lin P, Cai Z, Yi Q. Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy. Leukemia. 2009 Jul; 23(7):1320-8. PMID: 19225534; PMCID: PMC5890427.
      Citations: 13     Fields:    Translation:HumansCells
    23. Wang M, Zhang L, Han X, Yang J, Qian J, Hong S, Lin P, Shi Y, Romaguera J, Kwak LW, Yi Q. A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma. Clin Cancer Res. 2008 Apr 01; 14(7):2154-60. PMID: 18381957.
      Citations: 13     Fields:    Translation:HumansAnimals
    24. Zhou Y, Zhang L, Romaguera J, Delasalle K, Han X, Du X, Kwak L, Yi Q, Wang M. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond. Am J Hematol. 2008 Feb; 83(2):144-9. PMID: 17722077.
      Citations: 6     Fields:    Translation:HumansCells
    25. Wang M, Han XH, Zhang L, Yang J, Qian JF, Shi YK, Kwak LW, Romaguera J, Yi Q. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia. 2008 Jan; 22(1):179-85. PMID: 17898787.
      Citations: 29     Fields:    Translation:Animals
    26. Yang J, Zhang X, Wang J, Qian J, Zhang L, Wang M, Kwak LW, Yi Q. Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts. Blood. 2007 Oct 15; 110(8):3028-35. PMID: 17644731; PMCID: PMC2018676.
      Citations: 21     Fields:    Translation:HumansCells
    27. Qian J, Xie J, Hong S, Yang J, Zhang L, Han X, Wang M, Zhan F, Shaughnessy JD, Epstein J, Kwak LW, Yi Q. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood. 2007 Sep 01; 110(5):1587-94. PMID: 17515399; PMCID: PMC1975842.
      Citations: 53     Fields:    Translation:HumansAnimalsCellsPHPublic HealthCTClinical Trials
    28. Wang M, Zhang L, Han X, Yang J, Qian J, Hong S, Samaniego F, Romaguera J, Yi Q. Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways. Blood. 2007 Jun 15; 109(12):5455-62. PMID: 17317853.
      Citations: 16     Fields:    Translation:AnimalsCells
    29. Wu S, Guo W, Teraishi F, Pang J, Kaluarachchi K, Zhang L, Davis J, Dong F, Yan B, Fang B. Anticancer activity of 5-benzylidene-2-phenylimino-1, 3-thiazolidin-4-one (BPT) analogs. Med Chem. 2006 Nov; 2(6):597-605. PMID: 17105441.
      Citations: 2     Fields:    Translation:HumansCells
    30. Wang M, Zhou Y, Zhang L, Nguyen CA, Romaguera J. Use of bortezomib in B-cell non-Hodgkin's lymphoma. Expert Rev Anticancer Ther. 2006 Jul; 6(7):983-91. PMID: 16831071.
      Citations: 1     Fields:    Translation:Humans
    31. Huang X, Lin T, Gu J, Zhang L, Roth JA, Stephens LC, Yu Y, Liu J, Fang B. Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft. Gene Ther. 2002 Oct; 9(20):1379-86. PMID: 12365003.
      Citations: 11     Fields:    Translation:HumansAnimals
    32. Zhang L, Gu J, Lin T, Huang X, Roth JA, Fang B. Mechanisms involved in development of resistance to adenovirus-mediated proapoptotic gene therapy in DLD1 human colon cancer cell line. Gene Ther. 2002 Sep; 9(18):1262-70. PMID: 12215894.
      Citations: 16     Fields:    Translation:HumansCells
    33. Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy. Chinese Journal of Cancer. 34.
    34. CD4+ T cells play a crucial role for lenalidomide in vivo antitumor activity in murine multiple myeloma. Oncotarget. 6:36032-36040.
    35. Discovery of 4-(Piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine Derivatives as Akt Inhibitors. Archiv der Pharmazie. 349:356-362.
    36. Lenalidomide in relapsed or refractory mantle cell lymphoma. Therapeutic Advances in Hematology. 5:91-101.
    37. IL-15 enhances the antitumor effect of human antigen-specific CD8+ T cells by cellular senescence delay. OncoImmunology. 5.
    ZHANG's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (205)
    Co-Authors (39)
    Similar People (60)
    Same Department Expand Description